Open Access

Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target

  • Authors:
    • Xiaoxiao Du
    • Kuifeng He
    • Yingying Huang
    • Zhenzhen Xu
    • Mei Kong
    • Jing Zhang
    • Jiang Cao
    • Lisong Teng
  • View Affiliations

  • Published online on: January 20, 2020     https://doi.org/10.3892/ijo.2020.4965
  • Pages: 761-771
  • Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pancreatic cancer is a lethal solid malignancy with limited therapeutic options. The development of novel therapeutic drugs requires adequate new cell line models. A new pancreatic cancer cell line, designated PDXPC1, was established from one pancreatic ductal adenocarcinoma (PDAC) patient‑derived xenograft. The PDXPC1 cells were stably cultured for >2 years and had a stable short tandem repeat profile. The PDXPC1 cell line retained the key mutations of the primary tumor, along with the epithelial origin and other important protein expression. The PDXPC1 cells induced rapid in vivo tumor growth, both subcutaneously and orthotopically, in a mouse model with an elevated CA199 level. The PDXPC1 cells showed weak growth, invasion and migration potency compared to another pancreatic cancer cell line, but were relatively resistant to multiple anti‑cancer drugs. Interestingly, the MEK inhibitor trametinib significantly inhibited the proliferation of PDXPC1 cells, and not that of Panc‑1 cells, by inactivating MEK/ERK/MYC signaling and activating the apoptotic pathway via Bcl‑2 degradation. In conclusion, the PDXPC1 cell line, capturing the major characteristics of the primary tumor, may be a suitable tool for studying the underlying mechanisms of chemo‑resistance in PDAC and developing new targeted therapeutic options.
View Figures
View References

Related Articles

Journal Cover

March 2020
Volume 56 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Du, X., He, K., Huang, Y., Xu, Z., Kong, M., Zhang, J. ... Teng, L. (2020). Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target. International Journal of Oncology, 56, 761-771. https://doi.org/10.3892/ijo.2020.4965
MLA
Du, X., He, K., Huang, Y., Xu, Z., Kong, M., Zhang, J., Cao, J., Teng, L."Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target". International Journal of Oncology 56.3 (2020): 761-771.
Chicago
Du, X., He, K., Huang, Y., Xu, Z., Kong, M., Zhang, J., Cao, J., Teng, L."Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target". International Journal of Oncology 56, no. 3 (2020): 761-771. https://doi.org/10.3892/ijo.2020.4965